Effects of Parathyroid Hormone in Men With Osteoporosis
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH)
stimulates the formation of new bone. The purpose of this study is to compare the
bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men
with osteoporosis over a two-and-a-half year period.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)